Clinical pharmacology

HepQuant, LLC to Offer Mobile and Remote Test Administration in Clinical Trials via CVS Health’s Coram Clinical Trials (CCT)

Retrieved on: 
Tuesday, February 18, 2020
FDA, Medical devices, Health, Pharmaceutical, Clinical trials, Health, Clinical research, Clinical pharmacology, Drug discovery, Pharmaceutical industry, Design of experiments, Medical research, Clinical trial, Thomas Coram Foundation for Children, FDA, Medical devices, Health, Pharmaceutical, Clinical trials, Health, Clinical research, Clinical pharmacology, Drug discovery, Pharmaceutical industry, Design of experiments, Medical research, Clinical trial, Thomas Coram Foundation for Children

By offering administration solutions through Coram Clinical Trials, we hope to reduce the overall operational burden of testing in clinical trials.

Key Points: 
  • By offering administration solutions through Coram Clinical Trials, we hope to reduce the overall operational burden of testing in clinical trials.
  • Utilizing Coram Clinical Trials should also standardize administration techniques and equipment, and normalize administration costs.
  • HepQuant is now working with its SHUNT-V pivotal study sites to use Coram Clinical Trials for administration of its liver tests, and in the future will expand use and administration in other upcoming clinical trials.
  • Coram Clinical Trials is an affiliate of CVS Specialty Coram Infusion Services.

ScienceMedia IMPROVES Quality and Risk Mitigation for Clinical Trials

Retrieved on: 
Tuesday, February 18, 2020
Health, Pharmaceutical industry, Clinical research, Clinical pharmacology, Clinical trial, Design of experiments, Medical research

ORLANDO, Fla. and SAN DIEGO, Feb. 18, 2020 /PRNewswire/ -- Today at the 11th Annual SCOPE, Summit for Clinical Ops Executives, ScienceMedia , the leader in life sciences and clinical trial education, released significant updates to SMi Trial, a new approach to risk mitigation in clinical trials.

Key Points: 
  • ORLANDO, Fla. and SAN DIEGO, Feb. 18, 2020 /PRNewswire/ -- Today at the 11th Annual SCOPE, Summit for Clinical Ops Executives, ScienceMedia , the leader in life sciences and clinical trial education, released significant updates to SMi Trial, a new approach to risk mitigation in clinical trials.
  • SMi Trial has been used in numerous Phase I, II, and III clinical trials worldwide.
  • ScienceMedia draws on its expert team of clinical writers, instructional designers, and multimedia artists to produce impactful training on the highest risk areas of a clinical trial.
  • SMi Trial mitigates clinical risk and decreases trial cost by optimizing study compliance throughout the lifetime of your clinical trial.

IBM Study Advance Designed to Reduce the Time and Costs Associated with Clinical Trials

Retrieved on: 
Tuesday, February 18, 2020
Health, Clinical research, Computing, Medical research, Medical statistics, Clinical pharmacology, Clinical trial, Design of experiments, Pharmaceutical industry, IBM, Watson

ORLANDO, Fla., Feb.18, 2020 /PRNewswire/ -- IBM Watson Health (NYSE: IBM ) today unveiled its newest cloud-based technology IBM Study Advance at the 11th Annual Summit for Clinical Ops Executives (SCOPE) .

Key Points: 
  • ORLANDO, Fla., Feb.18, 2020 /PRNewswire/ -- IBM Watson Health (NYSE: IBM ) today unveiled its newest cloud-based technology IBM Study Advance at the 11th Annual Summit for Clinical Ops Executives (SCOPE) .
  • On average, a single protocol amendment to a Phase III clinical trial can result in approximately $500,000 (USD) in unplanned expenses and an additional 61 days to the project timeline.1 IBM Study Advance is designed to offer critical insights during the process of study design to help reduce the number of amendments during clinical trials.
  • "Breakdowns in the clinical trial process, including issues caused by study design decisions, may potentially delay access to life-changing therapies for patients.
  • IBM Study Advance aims to remove the barriers in clinical development to help researchers efficiently bring necessary therapies to patients."

AppBus and Plecosystems Partner to Accelerate Clinical Outcomes

Retrieved on: 
Tuesday, February 18, 2020
Health, Clinical research, Medical research, Clinical pharmacology, Pharmaceutical industry, Food and Drug Administration, Clinical trial, Design of experiments

Using the AppBus platform, Pleco can now increase the speed of application integrations for clinical trials.

Key Points: 
  • Using the AppBus platform, Pleco can now increase the speed of application integrations for clinical trials.
  • Further, the AppBus platform allows for the automation of complex processes, therefore improving the efficiency of clinical operations and allowing for cleaner data across studies.
  • "Every sponsor and CRO should have the opportunity to partner with AppBus, as they are extremely knowledgeable in all aspects of Clinical integrations," stated Ed Leftin, Director of IT at Ora Clinical.
  • "As the number of systems and overall complexity within clinical trials grows exponentially, AppBus and Pleco are redefining how guided process automation can accelerate and improve clinical outcomes," stated AppBus CEO, Bill Conners.

ClinOne brings medical-grade remote monitoring to clinical trials with the BioIntelliSense FDA-cleared BioSticker™ device

Retrieved on: 
Tuesday, February 18, 2020
Technology, Biotechnology, FDA, Health, Other Health, Pharmaceutical, Other Communications, Research, Medical devices, Software, Communications, Science, Data management, Clinical trials, Health, Medicine, Pharmaceutical industry, Clinical research, Clinical pharmacology, Clinical trial, Design of experiments, Monitoring, Food and Drug Administration

ClinOne announces today its strategic collaboration with BioIntelliSense to combine continuous health monitoring and clinical intelligence with the ClinOne ClinTrialConnect patient portal platform.

Key Points: 
  • ClinOne announces today its strategic collaboration with BioIntelliSense to combine continuous health monitoring and clinical intelligence with the ClinOne ClinTrialConnect patient portal platform.
  • The addition of the FDA-cleared BioSticker single-use device provides an effortless trial participant experience enabling 30-days of continuous vital sign monitoring.
  • The introduction of the BioIntelliSense Data-as-a-Service platform and BioSticker device closes the real-world data (RWD) gap in clinical trials by providing a comprehensive view of a patient's health status.
  • Through our combined capabilities, we can significantly reduce the cost of clinical trials by monitoring the patients and their well-being remotely through the FDA-cleared BioSticker device, according to Rob Bohacs, ClinOne.

OptimizeRx Launches EHR-Enabled Specialty Hub Enrollment Form

Retrieved on: 
Tuesday, February 18, 2020
Life sciences, Articles, Biopharmaceuticals, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Specialty drugs, Clinical pharmacology, Pharmacy, Specialty pharmacy, Medical prescription

Providers are often unaware that they must complete part of the enrollment form.

Key Points: 
  • Providers are often unaware that they must complete part of the enrollment form.
  • Lack of awareness and difficulty completing these forms are often barriers to successfully filling specialty prescriptions for patients.
  • The OptimizeRx hub-enrollment solution increases patient access to specialty drugs right at the point of care using technology to assist providers to easily route specialty scripts correctly to a hub or specialty pharmacy, noted Miriam Paramore, OptimizeRxs president.
  • The EHR specialty prescription enrollment capability is just the first technological advancement from the Innovation Lab that OptimizeRx is bringing to market in 2020.

Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Tuesday, February 18, 2020
Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry

The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.

Key Points: 
  • The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.
  • Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101.
  • STS101 has undergone extensive pre-clinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development.
  • Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina.

Surescripts Report Shows U.S. Patients Demand Greater Prescription Price Transparency

Retrieved on: 
Tuesday, February 18, 2020
Technology, General Health, Networks, Health, Health, Articles, Clinical pharmacology, Medical terminology, Pharmacy, Healthcare quality, Patient safety, Adherence, Medical prescription, Prescription drug prices in the United States, Patient-centered outcomes

Surescripts Prescription Price Transparency and the Patient Experience survey shows that patients want to talk about the price of a prescription with their provider to avoid the sticker shock and delays that can lead to medication non-adherence.

Key Points: 
  • Surescripts Prescription Price Transparency and the Patient Experience survey shows that patients want to talk about the price of a prescription with their provider to avoid the sticker shock and delays that can lead to medication non-adherence.
  • In fact, 41% of patients said they have referred other patients to their doctor because of conversations they had about price and lower-cost alternatives.
  • Prescription price transparency at the point of care is especially important to millennials and their choice of healthcare provider.
  • Download the report, Prescription Price Transparency and the Patient Experience , to see more patient perspectives on talking to their healthcare providers about drug cost.

Clinical Ink Announces Addition of New Module to Their Lumenis™ eSource Ecosystem

Retrieved on: 
Tuesday, February 18, 2020
Software, Research, Hardware, Pharmaceutical, Data management, Oncology, Technology, Medical devices, Clinical trials, Science, Biotechnology, FDA, Health, Health, Clinical research, Articles, Clinical pharmacology, Pharmaceutical industry, Health research, Clinical trial

Clinical Ink, a global clinical trial technology company, announces the addition of a new component to their Lumenis eSource Ecosystem .

Key Points: 
  • Clinical Ink, a global clinical trial technology company, announces the addition of a new component to their Lumenis eSource Ecosystem .
  • With the addition of eConsent, Clinical Inks Lumenis platform expands further, providing purpose-built solutions for your protocol and anytime, anywhere access to study data.
  • The new eConsent module comes just months after the EMA released an important qualification opinion in favor of using eSource DDC in clinical trials.
  • A unified, eSource technology must be considered by innovative companies to advance global clinical research, said Clinical Ink CEO Ed Seguine .

Curavit Clinical Research officially launches with a focus on virtual trials

Retrieved on: 
Tuesday, February 18, 2020
Health, Clinical research, Medical research, Clinical pharmacology, Medical statistics, Pharmaceutical industry, Clinical trial, Design of experiments

https://curavitclinicalresearch.com/abou t

Key Points: 
  • https://curavitclinicalresearch.com/abou t
    The $70 billion global clinical trials market continues to grow, while the success rate of trials continues to decline, often due to lack of enrollment and participation by patients and doctors.
  • New technologies and new approaches offer an opportunity to both increase success rates and decrease the costs of traditional clinical trials.
  • Just a small percentage of trials today, virtual trials are projected to increase geometrically due to their advantages.
  • Curavit Clinical Research takes a clean sheet approach to clinical trial design and execution.